Detailed price information for Gsk Plc ADR (GSK-N) from The Globe and Mail including charting and trades.
GSK plc (LSE:GSK) has received accelerated approval from the US Food and Drug Administration (FDA) for Nelkarmi (neladalkib), a targeted treatment for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). The approval covers patients who have previously received alectinib as their only ALK tyrosine kinase inhibitor (TKI), or at least two prior ALK inhibitors and platinum-based chemotherapy, in the unresectable locally advanced or metastat
GSK can now launch a new medicine in the U.S. for lung cancer, a move that bolsters its efforts to build a franchise in a disease that is the leading cause of cancer death.
Tipranks Press Release.
Emma Walmsley will join an exclusive club of CEOs who’ve led two corporate giants.
Ex-GSK chief Emma Walmsley was the first woman to run a major pharma company. Now she'll bring her transformation experience to hardware.
GSK plc has delivered strong multi year gains for shareholders, and the latest news around its cancer and specialty medicines raises a straightforward question for you as an investor. Is the current share price near £18.90 adequately supported by the drug maker's earnings power, or has sentiment moved ahead of what the income statement can justify? Over the past 3 years the stock has returned about 50.2%, which puts real weight on whether the underlying profits can sustain that kind of share...
HP said Walmsley, who was at the helm of drugmaker GSK from April 2017 until the end of 2025, will join the Palo Alto, Calif., company on Jan. 4.
HP Inc. named former GSK Plc chief executive officer Emma Walmsley as its new CEO, permanently filling the role after HP’s Enrique Lores departed earlier this year.
Mark Hartley weighs up the case for GSK shares after noticing a large discrepancy in broker targets. But are they focusing on the right thing? The post Brokers can’t agree on GSK shares but I’m watching its cancer pipeline appeared first on The Twelfth Magpie.
GSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here.
This is the newest page. Registered accounts read further back.